DLBCL - Primärtherapie
R-CHOEP–brut Studie
Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma; Eudra CT 2017-003256-22
OPTIMAL>60 Studie
Improvement of Outcome and Reduction of Toxicity in Elderly Patients with CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET based Reduction of Therapy in Combination with Vitamin D Substitution; EudraCT 2010-019587-36
DLBCL - Rezidivtherapie
NIVEAU Studie
Improvement of Outcome in Elderly Patients or Patients not eligible for high-dose chemotherapy in first Relapse or Progression by adding Nivolumab to Gemcitabine, Oxalipatin plus Rituximab in case of CD20+ Disease; EudraCT 2016-002272-27
MOR208204, , Morphosys-Studie/B-MInd
A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) – B-MIND; EudraCT 2014-004689-11
ZNS-Lymphom - Primärtherapie
MARTA Studie
Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients; EudraCT 2016-001628-72
Mantelzelllymphom - Primärtherapie
TRIANGLE Studie
Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing induction in generalized matle cell Lymphoma – a European mcl network study; EudraCT 2014-001363-12
Mantelzelllymphom - Rezidivtherapie
Follikuläres Lymphom - Rezidivtherapie
GAZAI
Therapy of NODAL Follicular Non Hodgkin Lymphoma (WHO grade ½) in Clinical Stage I/II using Response Adapted Involved Site Radiotherapy in Combination with Gazyvaro; EudraCT 2016-002059-89
PTLD2
Risk-Stratified sequential Treatment of Post-Transplant Lymphoproliferative Disease with 4 courses of Rituximab SC Followed by 4 couses of RituximabSC, 4 Courses of Rituximab SC combinated with CHOP-21 or 6 courses of Rituximab SC combinated with Alternating CHOP-21 and DHAOX: the PTLD-2 Trail; EudraCT 2013-004479-11
GO29781
An open-label, multicenter, phase i/ib trial evaluating the safety and pharmacokinetics of escalating doses of btct4465a as a single agent and combined with atezolizumab in patients with relapsed or refractory b-cell non-hodgkin’s lymphoma and chronic lymphocytic leukemia; EudraCT 2017-003267-35
Lymphomplasmozytisches Lymphom/ Waldenström - Rezidivtherapie